Brevan Howard Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Brevan Howard Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Sell	170,511 -105,722	-38%	-$6.16M	0.09%	125
2025 Q4	$14.9M	Buy	276,233 +203,575	+280%	+$9.79M	0.16%	81
2025 Q3	$3.28M	Sell	72,658 -90,594	-55%	-$4.23M	0.01%	378
2025 Q2	$7.56M	Buy	+163,252	New	+$8.01M	0.04%	245
2025 Q1	–	Sell	-142,886	Closed	-$8.08M	–	1176
2024 Q4	$8.08M	Buy	142,886 +106,230	+290%	+$5.94M	0.05%	86
2024 Q3	$1.9M	Buy	36,656 +30,129	+462%	+$1.41M	0.01%	293
2024 Q2	$271K	Buy	+6,527	New	+$292K	﹤0.01%	813
2024 Q1	–	Sell	-18,098	Closed	-$929K	–	1024
2023 Q4	$929K	Buy	18,098 +1,245	+7%	+$65.4K	0.01%	259
2023 Q3	$978K	Buy	+16,853	New	+$1.03M	0.01%	91

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brevan Howard Capital Management's BMY Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 38% in Q1 2026, selling an estimated $6.16M and leaving 170,511 shares worth $10.3M. The position accounts for 0.09% of the portfolio, ranked #125.

Brevan Howard Capital Management first reported a position in BMY in Q3 2023 and has held it in 9 quarters since. The position peaked at $14.9M in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Brevan Howard Capital Management held 170,511 shares of Bristol-Myers Squibb worth $10.3M as of Q1 2026.
Brevan Howard Capital Management sold 105,722 Bristol-Myers Squibb shares in Q1 2026, an estimated $6.16M.
Bristol-Myers Squibb made up 0.09% of Brevan Howard Capital Management's portfolio in Q1 2026, its #125 holding.
Brevan Howard Capital Management first reported a position in Bristol-Myers Squibb in Q3 2023 and has held it in 9 quarters since.
Brevan Howard Capital Management's Bristol-Myers Squibb position peaked at $14.9M in Q4 2025.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.